A Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease	Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Skin and Connective Tissue Diseases, Urogenital Diseases, acquired idiopathic inflammatory myopathy, anti-neutrophil cytoplasmic antibody-associated vasculitis, autoimmune disease, autoimmune disorder of the nervous system, cardiovascular disorder, central nervous system disorder, connective tissue disorder, glomerulonephritis, immune system disorder, kidney disorder, lupus nephritis, muscle tissue disorder, musculoskeletal system disorder, myositis disease, necrotizing vasculitis, nephritis, nervous system disorder, neuromuscular disease, skin disorder, skin vascular disease, spinal cord disorder, stiff-person syndrome, systemic lupus erythematosus, systemic sclerosis, urinary system disorder, vascular disorder, vasculitis	Enrolling by invitation	Phase 1	2026-03-19		NCT06375993

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Adicet Therapeutics	5

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Adicet Clinical Trials	Redwood City	United States	3
Roswell Park Comprehensive Cancer Center	Buffalo	United States	63